Cargando…
New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter
PURPOSE OF REVIEW: Idiopathic inflammatory myopathy (IIM) classification criteria have been a subject of debate for many decades. Despite several limitations, the Bohan and Peter criteria are still widely used. The aim of this review is to discuss the evolution of IIM classification criteria. RECENT...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857275/ https://www.ncbi.nlm.nih.gov/pubmed/29550929 http://dx.doi.org/10.1007/s11926-018-0726-4 |
_version_ | 1783307439384297472 |
---|---|
author | Leclair, Valérie Lundberg, Ingrid E. |
author_facet | Leclair, Valérie Lundberg, Ingrid E. |
author_sort | Leclair, Valérie |
collection | PubMed |
description | PURPOSE OF REVIEW: Idiopathic inflammatory myopathy (IIM) classification criteria have been a subject of debate for many decades. Despite several limitations, the Bohan and Peter criteria are still widely used. The aim of this review is to discuss the evolution of IIM classification criteria. RECENT FINDINGS: New IIM classification criteria are periodically proposed. The discovery of myositis-specific and myositis-associated autoantibodies led to the development of clinico-serological criteria, while in-depth description of IIM morphological features improved histopathology-based criteria. The long-awaited European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) IIM classification criteria were recently published. SUMMARY: The Bohan and Peter criteria are outdated and validated classification criteria are necessary to improve research in IIM. The new EULAR/ACR IIM classification criteria are thus a definite improvement and an important step forward in the field. |
format | Online Article Text |
id | pubmed-5857275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-58572752018-03-21 New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter Leclair, Valérie Lundberg, Ingrid E. Curr Rheumatol Rep Inflammatory Muscle Disease (R Aggarwal, Section Editor) PURPOSE OF REVIEW: Idiopathic inflammatory myopathy (IIM) classification criteria have been a subject of debate for many decades. Despite several limitations, the Bohan and Peter criteria are still widely used. The aim of this review is to discuss the evolution of IIM classification criteria. RECENT FINDINGS: New IIM classification criteria are periodically proposed. The discovery of myositis-specific and myositis-associated autoantibodies led to the development of clinico-serological criteria, while in-depth description of IIM morphological features improved histopathology-based criteria. The long-awaited European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) IIM classification criteria were recently published. SUMMARY: The Bohan and Peter criteria are outdated and validated classification criteria are necessary to improve research in IIM. The new EULAR/ACR IIM classification criteria are thus a definite improvement and an important step forward in the field. Springer US 2018-03-17 2018 /pmc/articles/PMC5857275/ /pubmed/29550929 http://dx.doi.org/10.1007/s11926-018-0726-4 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Inflammatory Muscle Disease (R Aggarwal, Section Editor) Leclair, Valérie Lundberg, Ingrid E. New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title | New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title_full | New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title_fullStr | New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title_full_unstemmed | New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title_short | New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter |
title_sort | new myositis classification criteria—what we have learned since bohan and peter |
topic | Inflammatory Muscle Disease (R Aggarwal, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857275/ https://www.ncbi.nlm.nih.gov/pubmed/29550929 http://dx.doi.org/10.1007/s11926-018-0726-4 |
work_keys_str_mv | AT leclairvalerie newmyositisclassificationcriteriawhatwehavelearnedsincebohanandpeter AT lundbergingride newmyositisclassificationcriteriawhatwehavelearnedsincebohanandpeter |